Evidence for therapeutic drug monitoring of targeted anticancer therapies

Bo Gao, Shang Yeap, Arthur Clements, Bavanthi Balakrishnar, Mark Wong, Howard Gurney

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its use for traditional anticancer therapies has been limited. Perhaps the most important obstacle is the impractical requirement of multiple blood samples to adequately define systemic exposure of drugs that have a short elimination half-life and are given by intermittent intravenous injections. However, the newer targeted anticancer therapies have different pharmacokinetic (PK) and dosing characteristics compared with traditional cytotoxic drugs, making it possible to estimate the steady-state drug exposure with a single trough-level measurement. Recent evidence indicates that certain PK parameters, including trough levels, are correlated with clinical outcomes for many of these agents, including imatinib, sunitinib, rituximab, and cetuximab. Although the current evidence is insufficient to mandate TDM in routine practice, a concerted investigation should be encouraged to determine whether the steady-state trough measurements of targeted agents will have a practical place in the clinical care of patients with cancer.

LanguageEnglish
Pages4017-4025
Number of pages9
JournalJournal of Clinical Oncology
Volume30
Issue number32
DOIs
Publication statusPublished - 10 Nov 2012
Externally publishedYes

Fingerprint

Drug Monitoring
Pharmacokinetics
Pharmaceutical Preparations
Immunosuppressive Agents
Intravenous Injections
Anticonvulsants
Half-Life
Patient Care
Therapeutics
Anti-Bacterial Agents
Neoplasms

Cite this

Gao, Bo ; Yeap, Shang ; Clements, Arthur ; Balakrishnar, Bavanthi ; Wong, Mark ; Gurney, Howard. / Evidence for therapeutic drug monitoring of targeted anticancer therapies. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 32. pp. 4017-4025.
@article{a36cacddf43b46d89e4a87c2e320f8b9,
title = "Evidence for therapeutic drug monitoring of targeted anticancer therapies",
abstract = "Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its use for traditional anticancer therapies has been limited. Perhaps the most important obstacle is the impractical requirement of multiple blood samples to adequately define systemic exposure of drugs that have a short elimination half-life and are given by intermittent intravenous injections. However, the newer targeted anticancer therapies have different pharmacokinetic (PK) and dosing characteristics compared with traditional cytotoxic drugs, making it possible to estimate the steady-state drug exposure with a single trough-level measurement. Recent evidence indicates that certain PK parameters, including trough levels, are correlated with clinical outcomes for many of these agents, including imatinib, sunitinib, rituximab, and cetuximab. Although the current evidence is insufficient to mandate TDM in routine practice, a concerted investigation should be encouraged to determine whether the steady-state trough measurements of targeted agents will have a practical place in the clinical care of patients with cancer.",
author = "Bo Gao and Shang Yeap and Arthur Clements and Bavanthi Balakrishnar and Mark Wong and Howard Gurney",
year = "2012",
month = "11",
day = "10",
doi = "10.1200/JCO.2012.43.5362",
language = "English",
volume = "30",
pages = "4017--4025",
journal = "Journal of Clinical Oncology",
issn = "1527-7755",
publisher = "American Society of Clinical Oncology",
number = "32",

}

Evidence for therapeutic drug monitoring of targeted anticancer therapies. / Gao, Bo; Yeap, Shang; Clements, Arthur; Balakrishnar, Bavanthi; Wong, Mark; Gurney, Howard.

In: Journal of Clinical Oncology, Vol. 30, No. 32, 10.11.2012, p. 4017-4025.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Evidence for therapeutic drug monitoring of targeted anticancer therapies

AU - Gao, Bo

AU - Yeap, Shang

AU - Clements, Arthur

AU - Balakrishnar, Bavanthi

AU - Wong, Mark

AU - Gurney, Howard

PY - 2012/11/10

Y1 - 2012/11/10

N2 - Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its use for traditional anticancer therapies has been limited. Perhaps the most important obstacle is the impractical requirement of multiple blood samples to adequately define systemic exposure of drugs that have a short elimination half-life and are given by intermittent intravenous injections. However, the newer targeted anticancer therapies have different pharmacokinetic (PK) and dosing characteristics compared with traditional cytotoxic drugs, making it possible to estimate the steady-state drug exposure with a single trough-level measurement. Recent evidence indicates that certain PK parameters, including trough levels, are correlated with clinical outcomes for many of these agents, including imatinib, sunitinib, rituximab, and cetuximab. Although the current evidence is insufficient to mandate TDM in routine practice, a concerted investigation should be encouraged to determine whether the steady-state trough measurements of targeted agents will have a practical place in the clinical care of patients with cancer.

AB - Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its use for traditional anticancer therapies has been limited. Perhaps the most important obstacle is the impractical requirement of multiple blood samples to adequately define systemic exposure of drugs that have a short elimination half-life and are given by intermittent intravenous injections. However, the newer targeted anticancer therapies have different pharmacokinetic (PK) and dosing characteristics compared with traditional cytotoxic drugs, making it possible to estimate the steady-state drug exposure with a single trough-level measurement. Recent evidence indicates that certain PK parameters, including trough levels, are correlated with clinical outcomes for many of these agents, including imatinib, sunitinib, rituximab, and cetuximab. Although the current evidence is insufficient to mandate TDM in routine practice, a concerted investigation should be encouraged to determine whether the steady-state trough measurements of targeted agents will have a practical place in the clinical care of patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=84869381780&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.43.5362

DO - 10.1200/JCO.2012.43.5362

M3 - Review article

VL - 30

SP - 4017

EP - 4025

JO - Journal of Clinical Oncology

T2 - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 1527-7755

IS - 32

ER -